“…Previous clinical data to date to support such an intervention comes from several studies evaluating cuffed AVG grafts ("Venaflo"; Bard Vascular, Tempe Arizona) [208][209][210] . In a recent randomized control trial evaluating cuffed vs non-cuffed AVG, cuffed AVGs showed better primary patency and cumulative survival 211 . Finally, results from a newly developed anastomotic implant device, "OptiflowTM" (Bioconnect Systems; Ambler, PA), to connect the artery and vein in AVFs and improve hemodynamics by providing a symmetric flow pattern, have shown a primary patency of 83% at 90 days 212 .…”